Interest spikes as new COVID-19 vaccines land Supplies are due to arrive in general practices this week, with GPs seeing a significant upturn in patients wishing to get boosted.
ATAGI gives Moderna bivalent vaccine green light There will soon be two bivalent vaccines available to people aged 12 and over.
Research shows boosters are ‘crucial’ for protecting vulnerable A new study has examined the impact of COVID-19 boosters for those with more than one chronic condition.
Novavax receives COVID-19 booster approval The protein-based vaccine is the third to gain TGA approval as a booster in Australia, following Pfizer and Moderna.
ATAGI expands fourth COVID vaccine dose eligibility The immunisation advisory group is now recommending a fourth COVID-19 vaccine dose for people with a range of immunocompromising conditions.
Extra booster dose recommended by ATAGI The rollout of additional COVID-19 vaccine doses for those ‘at greatest risk of severe illness’ will commence ahead of winter to tie in with flu vaccination.
Novavax given limited approval as booster New ATAGI advice permits Novavax for third dose and encourages those who had AstraZeneca as primary course to take mRNA booster.
What ‘up-to-date’ vaccination status means for GPs New ATAGI guidance on boosters and vaccination status has been approved by National Cabinet. Here is the rationale and how it is likely to work.
Teenage social patterns make boosters a ‘good idea’, expert says GPs are soon expected to start administering booster doses to those aged 16–17 following the TGA’s provisional approval of Pfizer.
COVID vaccination for immunocompromised cancer patients Oncologist Professor Eva Segelov details important clinical information specific to this vulnerable cohort.